Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

Julie R. Brahmer, Christina Lacchetti, Bryan J. Schneider et al. · Journal of Clinical Oncology · 2018 · 3.6K citations · Full text

Immunohematology, Cancer Immunosurveillance, Autoimmune Disease +15

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

John B.A.G. Haanen, Franck Carbonnel, Caroline Robert et al. · Annals of Oncology · 2017 · 2.3K citations

Immunotoxicology, Immunodeficiencies, Immunology +6

Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

Ethan Basch, Bryce B. Reeve, Sandra A. Mitchell et al. · JNCI Journal of the National Cancer Institute · 2014 · 1.1K citations · Full text

Cancer Management, Epidemiology Of Cancer, Cancer Registration +19

Validity and Reliability of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

Amylou C. Dueck, Tito R. Mendoza, Sandra A. Mitchell et al. · JAMA Oncology · 2015 · 979 citations · Full text

Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer

Koji Haratani, Hidetoshi Hayashi, Yasutaka Chiba et al. · JAMA Oncology · 2017 · 978 citations